In this review:
TLR-7 agonist increases immunemediated clearance of HIV-infected cells
DOR vs. boosted DRV as initial therapy
Elsulfavirine vs. EFV combined with TDF/FTC
TAF vs. TDF-based ART as initial therapy
Switching to RPV and DTG (SWORD 1 and 2)
Switching to DTG monotherapy
Monoclonal antibody to preventvirological rebound
DRV and MI
ATHENA CV disease modelling
Doxycycline to prevent STIs in menreceiving PrEP
Please login below to download this issue (PDF)